CPIGHZ PTO/SB/21 (09-04)

Approved for use Through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	-,,	Application Number	er	10/526,74	1	1
TRANSMITTAL	Filing Date		March 4, 2	2005	一	
FORM	First Named Inven	tor	ABURATA			
NOV 2 8 2006 (1)	Art Unit		1642			
(to be use for all correspondence after	Examiner Name		Peter J. Reddig			
Total Der of Pages in This Submiss	ion 6	Attorney Docket N	umber	392.1002		
ENCLOSURES (check all that apply)						$\stackrel{\frown}{}$
Fee Transmittal Form Drawing				After Alle	owance Communication to	гс
Fee Attached	Licensing-related Papers		Appeal Communication to Board			
Amendment / Reply		'		of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)		
After Final	_	Petition to Convert to a Provisional Application		Proprietary Information		
		Attorney, Revocation f Correspondence Add	ress	Status Letter		
Extension of Time Request	Terminal Disclaimer		Other Enclosure(s) (please identify below):			
Express Abandonment Request	Request for Refund		references;	and copies of nine (9) cited		
☐ Information Disclosure Statement	CD, Number of CD(s)			PO search report (5 pages) ceipt Postcard		
Minimum piscosare diatement	☐ Landscape Table on CD			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
Certified Copy of Priority Document(s)	Remarks	,				$\neg$
Reply to Missing Parts/						
Incomplete Application Reply to Missing Parts						
under 37 CFR1.52 or 1.53						
SIGI	NATURE OF	APPLICANT, ATTOI	RNEY, OF	R AGENT		
Firm Davidson Davidson & Kappel, LLC						
Signature	Will					
Printed Name						
Date         November 24, 2006         Reg. No.         36,968						
CERTIFICATE OF TRANSMISSION/MAILING						
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.						
Signature Word Willy 6						
Typed or printed name Morey B. V			Date	November 24, 2006		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re: Application of:

Hiroyuki ABURATANI et al.

Serial No.:

10/526,741

Filed:

March 4, 2005

For:

ANTIBODY AGAINST SECRETED N-

TERMINAL PEPTIDE OF GPC3 PRESENT IN BLOOD OR C-TERMINAL PEPTIDE OF GPC3

Examiner:

Peter J. Reddig

Art Unit:

1642

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 November 24, 2006

## SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

SIR:

In accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby submits this Supplemental Information Disclosure Statement, including two (2) sheets of Form PTO-1449, for consideration by the Examiner in connection with the above-identified patent application.

In accordance with 37 C.F.R. § 1.97(e), Applicants state that each reference cited in this Information Disclosure Statement, copies of which are enclosed herewith, was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement, namely a Supplementary Search Report dated August 31, 2006 from the European Patent Office for European Patent Application No. 03794236.4 corresponding to the above-identified patent application, a copy of which EPO Search Report is also enclosed.

his information disclosure statement is being submitted under 37 C.F.R. § 1.97(c), before the mailing date of any final action, and, therefore, no fee is due. If any fees are due, the Commissioner is authorized to charge such fees to Deposit Account No. 50-0552.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By:

Morey B. Wildes Reg. No. 36,968

DAVIDSON, DAVIDSON & KAPPEL, LLC 485 Seventh Avenue, 14<sup>th</sup> Floor New York, NY 10018 (212) 736-1940

NOV 2 8 2006

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Complete if Known 10/526,741

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number

stitute for form 1449A/PTO

1

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Filing Date November 14, 2005

First Named Inventor Hiroyuki ABURATANI, et al.

Art Unit 1642

(Use as many sheets as necessary)

US-

of | 2

Examiner Name Peter J. Reddig

Attorney Docket Number 392.1002

**U.S. PATENT DOCUMENTS** Name of Patentee or Applicant of **Document Number** Publication Date Pages, Columns, Lines, Where Relevant Cite No.1 Examine Cited Document Initials \* MM-DD-YYYY Passages or Relevant Figures Appear Number - Kind Code2 (if known) US-US-ับร US-US-US-US-US-US-US-US-US-US-US-US-US-US-US-US-

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document		
		W0 2004/0222597	03-18-2004	Chugai Seiyaku Kabushiki Kaisha		
		W0 00/23109	04-27-2000	The Regents of the Univ. of California		·
	<u> </u>					
	<b></b>					

Examiner Signature Date Considered	
------------------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449B/PTO Complete if Known Application Number 10/526,741 INFORMATION DISCLOSURE November 14, 2005 Filing Date STATEMENT BY APPLICANT Hiroyuki ABURATANI, et al. First Named Inventor Art Unit 1642 (Use as many sheets as necessary) Examiner Name Peter J. Reddig of 392.1002 Sheet Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		Lage et al.: "Expression of a glypican-related 62-kDa antigen is decreased in hepatocellular carcinoma in correspondence to the grade of tumor differentiation" Virchows Archiv, vol. 438, no 6, June 2001, pages 568-573.			
		Filmus J: "Glypicans in growth control and cancer", Glycobiology, vol. 11, no. 3 March 2001,pages 19R-23R.			
	_	Blackhall F H et al.: "Heparan sulfate proteoglycans and cancer", British Journal of Cancer, vol. 85, no. 8, 19 October 2001, pages 1094-1098,			
		Xiang et al.: "Glypican-3 expression is silenced in human breast cancer", ONCOGENE, vol. 20, no. 50, 1 November 2001, pages 7408-7412.			
		Powell et al.: "Oligonucleotide microarray analysis of lung adenocarcinoma in smokers and nonsmokers identifies GPC3 as a potential lung tumor suppressor," Chest, vol. 121, no. 3 Suppl. March 2002, pages 6S-7S.			
		Lin H et al.: "Frequent silencing of the GPC3 gene in ovarian cancer cell lines", Cancer Research, vol. 59, no. 4, 15 February 1999, pages 807-810.			
		Zhu Z et al.: "Glypican-3 expression is markedly decreased in human gastric cancer but not in esophageal cancer," Amercian Journal Of Surgery, vol. 184, no. 1, July 2002, pages 78-83.			
			<del></del>		

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

'Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.